• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

AstraZeneca

1,629.50 SEK+1.68 %15.7, 17.29
Less than 1K followers

AZN

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+1.68 %
-3.81 %
-12.51 %
-7.68 %
-4.34 %
+18.25 %
+17.31 %
+57.14 %
+8,816.31 %

AstraZeneca is a global pharmaceutical company focused on the research, development and marketing of prescription medicines, primarily for the treatment of diseases in the therapeutic areas of respiratory, cardiovascular/metabolic and cancer. In addition to its core business, the company also has a focus on the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in all global regions and is headquartered in Cambridge, UK.

Read more
Market cap
2.53T SEK
Turnover
812.78M SEK
Revenue
540.24B
EBIT %
23.4 %
P/E
26.84
Dividend yield-%
1.81 %
Revenue and EBIT-%
EPS and dividend
Financial calendar
27.7
2026

Interim report Q2'26

30.10
2026

Interim report Q3'26

All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Regulatory press release20.11.2025, 08.00

AstraZeneca: Koselugo (selumetinib) approved in the US

AstraZeneca
Regulatory press release14.07.2025, 08.00

AstraZeneca: Baxdrostat met primary endpt in BaxHTN PhIII trial

AstraZeneca
Regulatory press release24.06.2025, 08.00

AstraZeneca: Datroway approved in US for EGFRm lung cancer

AstraZeneca

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release28.02.2025, 14.06

AstraZeneca: Enhertu recommended in EU in post-ET breast cancer

AstraZeneca
Regulatory press release06.02.2025, 08.00

AstraZeneca: Final Results

AstraZeneca
Regulatory press release07.10.2024, 10.30

AstraZeneca licenses lipid lowering Lp(a) asset

AstraZeneca
Regulatory press release07.03.2024, 12.00

AstraZeneca: Notice of AGM

AstraZeneca
Regulatory press release21.02.2024, 08.00

AstraZeneca: Filing of Form 20-F with SEC

AstraZeneca
Regulatory press release09.11.2023, 08.00

AstraZeneca: 9M and Q3 2023 results

AstraZeneca
Press release25.07.2022, 08.11

AstraZeneca: Tezspire recommended for approval in the EU by CHMP for the treatment of severe asthma

AstraZeneca
Press release25.07.2022, 08.06

AstraZeneca: Ultomiris recommended for approval in the EU by CHMP for the treatment of adults with generalised myasthenia gravis

AstraZeneca
Press release25.07.2022, 08.01

AstraZeneca: Enhertu granted Priority Review in the US for patients with HER2-low metastatic breast cancer

AstraZeneca
Regulatory press release19.07.2022, 08.01

AstraZeneca: Enhertu approved in the EU for patients with HER2-positive metastatic breast cancer treated with one or more prior anti-HER2-based regimens

AstraZeneca
Press release16.05.2022, 08.00

AstraZeneca: PT027, a novel fixed-dose combination of albuterol and budesonide, used as an as-needed rescue medicine, significantly reduced the risk of a severe exacerbation

AstraZeneca
Regulatory press release14.12.2020, 10.00

AstraZeneca to acquire Alexion Pharmaceuticals Inc

AstraZeneca
Regulatory press release03.12.2019, 10.00

AstraZeneca divests Seroquel rights: US and Canada

AstraZeneca
Regulatory press release23.10.2018, 11.00

AstraZeneca Extends Innate Pharma Collaboration

AstraZeneca
Regulatory press release01.10.2018, 11.00

AstraZeneca PLC Announces Agreement with Cheplapharm for rights to Atacand in 28 European countries completed

AstraZeneca
Regulatory press release24.09.2018, 11.00

Farxiga gets positive result in DECLARE-TIMI 58

AstraZeneca